Glasdegib: all 22 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMMLCompletedNCT04842604Phase 3Results posted
- CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid LeukemiaActive, not recruitingNCT04231851Phase 2Results posted
- Glasdegib for Chronic Graft-Versus-Host DiseaseTerminatedNCT04111497Phase 1/2Results posted
- GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid LeukemiaTerminatedNCT04051996Phase 2Results posted
- A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT03416179Phase 3Results posted
- OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT03390296Phase 1/2Results posted
- Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid LeukemiaCompletedNCT03226418Phase 2Results posted
- A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML PatientsCompletedNCT02367456Phase 1Results posted
- Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With RuxolitinibTerminatedNCT02226172Phase 2Results posted
- Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)CompletedNCT01842646Phase 2Results posted
- PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell TransplantCompletedNCT01841333Phase 2Results posted
- A Study Of PF-04449913 Administered Alone In Select Solid TumorsCompletedNCT01286467Phase 1Results posted
- A Study Of PF-04449913 In Select Hematologic MalignanciesCompletedNCT00953758Phase 1Results posted
- Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)TerminatedNCT04093505Phase 3
- Molecular Profiling of Advanced Soft-tissue SarcomasCompletedNCT03784014Phase 3
- A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of GlasdegibCompletedNCT03627754Phase 1
- Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed GlioblastomaCompletedNCT03466450Phase 1/2
- Glasdegib in Refractory Patients With Sclerotic Chronic Graft-Versus-Host DiseaseStatus unknownNCT03415867Phase 1/2
- Glasdegib Absolute Bioavailability StudyCompletedNCT03270878Phase 1
- Understanding The Effect Of A Strong CYP3A4 Inducer On Glasdegib PharmacokineticsCompletedNCT02430545Phase 1
- A Study To Understand How Radiolabelled PF-04449913 Is Taken Up By The Body, Broken Down And Then Removed From The BodyCompletedNCT02110342Phase 1
- Study To Determine The Effect Of Food And Strong CYP3A4 Enzyme Inhibitor On PF-04449913 Drug LevelsCompletedNCT01749085Phase 1